- Home
- BPTH vs SCNI Comparison
BPTH vs SCNI Comparison
Compare BPTH & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- SCNI
- Stock Information
- Founded
- BPTH 2007
- SCNI 2003
- Country
- BPTH United States
- SCNI Israel
- Employees
- BPTH N/A
- SCNI N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BPTH Health Care
- SCNI Health Care
- Exchange
- BPTH Nasdaq
- SCNI Nasdaq
- Market Cap
- BPTH 4.0M
- SCNI 3.5M
- IPO Year
- BPTH N/A
- SCNI N/A
- Fundamental
- Price
- BPTH $0.82
- SCNI $3.46
- Analyst Decision
- BPTH Strong Buy
- SCNI
- Analyst Count
- BPTH 2
- SCNI 0
- Target Price
- BPTH $30.00
- SCNI N/A
- AVG Volume (30 Days)
- BPTH 107.7K
- SCNI 11.4K
- Earning Date
- BPTH 11-15-2024
- SCNI 11-22-2024
- Dividend Yield
- BPTH N/A
- SCNI N/A
- EPS Growth
- BPTH N/A
- SCNI N/A
- EPS
- BPTH N/A
- SCNI N/A
- Revenue
- BPTH N/A
- SCNI $284,000.00
- Revenue This Year
- BPTH N/A
- SCNI N/A
- Revenue Next Year
- BPTH N/A
- SCNI N/A
- P/E Ratio
- BPTH N/A
- SCNI N/A
- Revenue Growth
- BPTH N/A
- SCNI N/A
- 52 Week Low
- BPTH $0.61
- SCNI $2.23
- 52 Week High
- BPTH $12.40
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- BPTH 40.36
- SCNI 55.00
- Support Level
- BPTH $0.74
- SCNI $2.70
- Resistance Level
- BPTH $0.85
- SCNI $3.57
- Average True Range (ATR)
- BPTH 0.09
- SCNI 0.24
- MACD
- BPTH -0.01
- SCNI 0.01
- Stochastic Oscillator
- BPTH 53.85
- SCNI 75.88
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.